 Under an individual patient expanded access program, Tiziana Life Sciences plc NASDAQ: TLSA has dosed the first patient with secondary progressive multiple sclerosis with nasally administered foralumab. Nasal Foralumab 50 mcg 25 mcgnostril will be administered in 3-week cycles, three timesweek dosing for the first two weeks followed by one week of a rest period. 